Browse by Title

203 results found

Type here to filter the list

#
7th Nursing & Allied Health Symposium - A Sprint and a Marathon: Building Resilience

Monica Morris, MSc, RN – Myeloma UK ### 1408999###Co-Chair###Clinical Practice Services ###Myeloma UK###
Co-Chair: Monica Morris, MSc, RN – Myeloma UK
### @@@ Ioanna Tsatsou ### 1996608###Co-Chair#########
Co-Chair: Ioanna Tsatsou
###
7th Nursing & Allied Health Symposium - Building Better Lives

Tiffany Richards ### 1409000###Co-Chair#########
Co-Chair: Tiffany Richards
### @@@ Andrea D. Preston, MRPharmS (Consultant) (she/her/hers) – NHS / Sanius Health ### 1998508###Co-Chair###Myeloma Specialist Pharmacist / Head of Patient Innovation & Care###NHS / Sanius Health###
Co-Chair: Andrea D. Preston, MRPharmS (Consultant) (she/her/hers) – NHS / Sanius Health
### she/her/hers
7th Nursing & Allied Health Symposium - Strengthening the Host

Beth Faiman, PhD, MSN, APN-BC,BMTCN, AOCN, FAAN, FAPO – Cleveland Clinic Taussig Cancer Institute, Department of Hematology and Medical Oncology ### 1408996###Co-Chair###Nurse Practitioner and Researcher###Cleveland Clinic Taussig Cancer Institute, Department of Hematology and Medical Oncology###
Co-Chair: Beth Faiman, PhD, MSN, APN-BC,BMTCN, AOCN, FAAN, FAPO – Cleveland Clinic Taussig Cancer Institute, Department of Hematology and Medical Oncology
### @@@ Matthias Hellberg-Naegele, MSc – Comprehensive Cancer Center Zurich ### 1409002###Co-Chair###Clinical Nurse Specialist###Comprehensive Cancer Center Zurich###
Co-Chair: Matthias Hellberg-Naegele, MSc – Comprehensive Cancer Center Zurich
###
A
Abstract Session 1: MRD and risk stratification

Morie A. Gertz, MD, MACP (he/him/his) – Mayo Clinic ### 1442939###Co-Chair###Division of Hematology, Department of Internal Medicine###Mayo Clinic###
Co-Chair: Morie A. Gertz, MD, MACP (he/him/his) – Mayo Clinic
### he/him/his @@@ Hartmut Goldschmidt, MD – Department of Medicine V, University Hospital Heidelberg; and National Center for Tumor Diseases (NCT) ### 1441836###Co-Chair###Head of the GMMG Studygroup, Department of Medicine V### Department of Medicine V, University Hospital Heidelberg; and National Center for Tumor Diseases (NCT)###
Co-Chair: Hartmut Goldschmidt, MD – Department of Medicine V, University Hospital Heidelberg; and National Center for Tumor Diseases (NCT)
###
Abstract Session 2: Biology

Annemiek Broijl, MD, PhD (she/her/hers) – ErasmusMC ### 1949878###Co-Chair###Hematologist###ErasmusMC###
Co-Chair: Annemiek Broijl, MD, PhD (she/her/hers) – ErasmusMC
### she/her/hers @@@ Lugui Qiu, MD (he/him/his) – Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences. ### 1409100###Co-Chair###Department Head###Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences.###
Co-Chair: Lugui Qiu, MD (he/him/his) – Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences.
### he/him/his
Abstract Session 3: Novel combinations, access and long term outcomes

Gordon Cook, PhD – Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK ### 1395086###Co-Chair###Clinical Professor###Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK###
Co-Chair: Gordon Cook, PhD – Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK
### @@@ Eirini Katodritou, MD, PhD (she/her/hers) – Department of Hematology, Theagenion Cancer Hospital, Thessaloniki, Greece ### 1442719###Co-Chair###Hematology Consultant###Department of Hematology, Theagenion Cancer Hospital, Thessaloniki, Greece###
Co-Chair: Eirini Katodritou, MD, PhD (she/her/hers) – Department of Hematology, Theagenion Cancer Hospital, Thessaloniki, Greece
### she/her/hers
Abstract Session 4: Genomics

Masood A. Shammas, PhD – Dana Farber Cancer Institute and VA Boston Healthcare System, Boston, MA, USA ### 1409103###Co-Chair###Lead Scientist###Dana Farber Cancer Institute and VA Boston Healthcare System, Boston, MA, USA###
Co-Chair: Masood A. Shammas, PhD – Dana Farber Cancer Institute and VA Boston Healthcare System, Boston, MA, USA
### @@@ Mark Bustoros, MD – Meyer Cancer Center, Weill Cornell Medicine, Cornell University ### 1395121###Co-Chair###Assistant Professor Of Medicine### Meyer Cancer Center, Weill Cornell Medicine, Cornell University###
Co-Chair: Mark Bustoros, MD – Meyer Cancer Center, Weill Cornell Medicine, Cornell University
###
Abstract Session 5: Immune Therapies

Katja Weisel, MD (she/her/hers) – University Medical Center of Hamburg-Eppendorf, Hamburg, Germany ### 1441837###Co-Chair###Deputy Director###University Medical Center of Hamburg-Eppendorf, Hamburg, Germany###
Co-Chair: Katja Weisel, MD (she/her/hers) – University Medical Center of Hamburg-Eppendorf, Hamburg, Germany
### she/her/hers @@@ Simon J. Harrison, MBBS, MRCP(uk), FRCPath(uk), FRACP, PhD (he/him/his) – Peter MacCallum Cancer Centre ### 1395103###Co-Chair###Director, Centre of Excellence in Cellular Immunotherapy###Peter MacCallum Cancer Centre###
Co-Chair: Simon J. Harrison, MBBS, MRCP(uk), FRCPath(uk), FRACP, PhD (he/him/his) – Peter MacCallum Cancer Centre
### he/him/his
Abstract Session 6: Immune

Eileen M. Boyle, MD PhD – UCL Cancer Institute ### 1661107###Co-Chair###Principal Clinical Research Fellow###UCL Cancer Institute###
Co-Chair: Eileen M. Boyle, MD PhD – UCL Cancer Institute
### @@@ Fanghuang Zhan, MD & PhD (he/him/his) – University of Arkasas Medical Sciences ### 1954267###Co-Chair###Professor###University of Arkasas Medical Sciences###
Co-Chair: Fanghuang Zhan, MD & PhD (he/him/his) – University of Arkasas Medical Sciences
### he/him/his
Aging of the general population and its impact on MM treatment

Yael C. Cohen, MD – Tel- Aviv Sourasky (Ichilov) Medical Center, and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel ### 1441834###Speaker###Director of Myeloma Service###Tel- Aviv Sourasky (Ichilov) Medical Center, and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel###
Speaker: Yael C. Cohen, MD – Tel- Aviv Sourasky (Ichilov) Medical Center, and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
###
AML and MRD

Jacqueline Cloos, PhD (she/her/hers) – Amsterdam UMC, location VUMC, Cancer Center Amsterdam ### 2122796###Speaker###Principal investigator###Amsterdam UMC, location VUMC, Cancer Center Amsterdam###
Speaker: Jacqueline Cloos, PhD (she/her/hers) – Amsterdam UMC, location VUMC, Cancer Center Amsterdam
### she/her/hers
Amyloidosis

Vaishali Sanchorawala, MD (she/her/hers) – Boston University Chobanian & Avedisian School of Medicine ### 1395067###Speaker###Director, Amyloidosis Center,### Boston University Chobanian & Avedisian School of Medicine###
Speaker: Vaishali Sanchorawala, MD (she/her/hers) – Boston University Chobanian & Avedisian School of Medicine
### she/her/hers
Audience Q&A
Audience Q&A
Audience Q&A
Audience Q&A
Audience Q&A
Audience Q&A
Audience Q&A
B
BCMA-targeted treatment options for elderly patients in early RRMM

Hang Quach, MBBS(Hons) SpecCertOC FRACP FRCPA MD – St Vincent’s Hospital Melbourne, University of Melbourne, VIC, Australia ### 1395163###Speaker###Director of Haematology###St Vincent’s Hospital Melbourne, University of Melbourne, VIC, Australia###
Speaker: Hang Quach, MBBS(Hons) SpecCertOC FRACP FRCPA MD – St Vincent’s Hospital Melbourne, University of Melbourne, VIC, Australia
###
C
Career Development Workshop: Nuts and bolts of developing a clinical trial

Marc S. Raab, MD (he/him/his) – Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany and Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany ### 1441863###Speaker###Group leader###Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany and Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany###
Speaker: Marc S. Raab, MD (he/him/his) – Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany and Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany
### he/him/his @@@ Charlotte Pawlyn, PhD, FRCP, FRCPath – The Institute of Cancer Research ### 1395074###Speaker###Research Team Leader and Consultant Haematologist###The Institute of Cancer Research###
Speaker: Charlotte Pawlyn, PhD, FRCP, FRCPath – The Institute of Cancer Research
###
Career Development Workshop: Setting up your laboratory research program

Paola Neri, MD PhD – Arnie Charbonneau Cancer Research Institute, University of Calgary ### 1409064###Speaker###Associate Professor###Arnie Charbonneau Cancer Research Institute, University of Calgary###
Speaker: Paola Neri, MD PhD – Arnie Charbonneau Cancer Research Institute, University of Calgary
### @@@ Mehmet K. Samur, PhD – Dana-Farber Cancer Institute ### 1395042###Speaker###Senior Research Scientist###Dana-Farber Cancer Institute###
Speaker: Mehmet K. Samur, PhD – Dana-Farber Cancer Institute
###
Career Development Workshop: The art of writing grants

Jens Lohr, MD, PhD – Dana-Farber Cancer Institute ### 1395128###Speaker###Assistant Professor###Dana-Farber Cancer Institute###
Speaker: Jens Lohr, MD, PhD – Dana-Farber Cancer Institute
### @@@ Mattia D'Agostino, MD – University of Turin ### 1949896###Speaker###Assistant professor###University of Turin###
Speaker: Mattia D'Agostino, MD – University of Turin
###
Challenges in MM

Shaji K. Kumar, MD – Mayo Clinic, Rochester, MN, US ### 1395048###Chair###Professor of Medicine/Consultant###Mayo Clinic, Rochester, MN, US###
Chair: Shaji K. Kumar, MD – Mayo Clinic, Rochester, MN, US
### @@@ Francesca Gay, MD – Division of Hematology 1, Clinical trial unit AOU città della salute e della scienza, University of Torino ### 1441897###Co-Chair###Professor / Hematologist###Division of Hematology 1, Clinical trial unit AOU città della salute e della scienza, University of Torino###
Co-Chair: Francesca Gay, MD – Division of Hematology 1, Clinical trial unit AOU città della salute e della scienza, University of Torino
###
Charting the genetic evolution in myeloma cell

Faith E. Davies, MD (she/her/hers) – Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA ### 1395145###Speaker###Professor of Medicine, Director of the Center for Blood Cancers Director of the Clinical Myeloma Pro###Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA###
Speaker: Faith E. Davies, MD (she/her/hers) – Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA
### she/her/hers
Close

Tracy King, PhD, MN, RN – Royal Prince Alfred Hospital, The University of Sydney ### 1408995###Speaker###Myeloma Nurse Consultant, Clinical Associate Professor###Royal Prince Alfred Hospital, The University of Sydney###
Speaker: Tracy King, PhD, MN, RN – Royal Prince Alfred Hospital, The University of Sydney
###
Closing Ceremony
Closing Remarks
D
Deciphering the human plasma cell niche and its transformation in multiple myeloma by highly multiplexed tissue imaging

Marc-A. Baertsch, MD – German Cancer Research Center (DKFZ) ### 1443167###Speaker###Physician Scientist###German Cancer Research Center (DKFZ)###
Speaker: Marc-A. Baertsch, MD – German Cancer Research Center (DKFZ)
###
Defining high risk and ultra-high risk MM

Martin F. Kaiser, MD, FRCP, FRCPath – The Institute of Cancer Research; Royal Marsden Hospital ### 1395056###Speaker###Consultant Haematologist###The Institute of Cancer Research; Royal Marsden Hospital ###
Speaker: Martin F. Kaiser, MD, FRCP, FRCPath – The Institute of Cancer Research; Royal Marsden Hospital
###
Defining the myeloma cell proteome

Arun P. Wiita, MD, PhD – University of California San Francisco, San Francisco, CA, USA ### 1395046###Speaker###Associate Professor, Department of Laboratory Medicine###University of California San Francisco, San Francisco, CA, USA###
Speaker: Arun P. Wiita, MD, PhD – University of California San Francisco, San Francisco, CA, USA
###
Delivery of long-term therapies: case-based presentations - Nurse Practitioner

Charise Gleason, NP-C – Winship Cancer Institute of Emory University ### 1443929###Speaker###Chief Advance Practice Providers###Winship Cancer Institute of Emory University###
Speaker: Charise Gleason, NP-C – Winship Cancer Institute of Emory University
###
Delivery of long-term therapies: case-based presentations - Pharmacist

Houry Leblebjian ### 1998510###Speaker#########
Speaker: Houry Leblebjian
###
Discuss abstracts in context

S. Vincent Rajkumar, MD – Mayo Clinic ### 1949877###Speaker###Edward W. and Betty Knight Scripps Professor of Medicine###Mayo Clinic###
Speaker: S. Vincent Rajkumar, MD – Mayo Clinic
###
Discuss abstracts in context

Gareth Morgan, MD, PHD, FRCP, FRCPATH (he/him/his) – NYU Langone Health Perlmutter Cancer Center ### 1395144###Speaker###Professor of Medicine, Director of Myeloma Research###NYU Langone Health Perlmutter Cancer Center###
Speaker: Gareth Morgan, MD, PHD, FRCP, FRCPATH (he/him/his) – NYU Langone Health Perlmutter Cancer Center
### he/him/his
Discuss abstracts in context

Francesca Gay, MD – Division of Hematology 1, Clinical trial unit AOU città della salute e della scienza, University of Torino ### 1441897###Speaker###Professor / Hematologist###Division of Hematology 1, Clinical trial unit AOU città della salute e della scienza, University of Torino###
Speaker: Francesca Gay, MD – Division of Hematology 1, Clinical trial unit AOU città della salute e della scienza, University of Torino
###
Discuss abstracts in context

Leif Bergsagel, MD – Mayo Clinic Arizona ### 1395045###Speaker###Professor of Medicine###Mayo Clinic Arizona###
Speaker: Leif Bergsagel, MD – Mayo Clinic Arizona
###
Discuss abstracts in context

Noopur Raje, MD – Massachusetts General Hospital Cancer Center ### 1395114###Speaker###Director, Center for Multiple Myeloma###Massachusetts General Hospital Cancer Center###
Speaker: Noopur Raje, MD – Massachusetts General Hospital Cancer Center
###
Discuss abstracts in context

Sagar Lonial, MD, FACP – Emory University School of Medicine, Atlanta, GA, USA ### 1395113###Speaker###Professor and Chair###Emory University School of Medicine, Atlanta, GA, USA###
Speaker: Sagar Lonial, MD, FACP – Emory University School of Medicine, Atlanta, GA, USA
###
E
EHA-IMS Symposium

Pieter Sonneveld, MD, PhD (he/him/his) – EMN ### 1395080###Co-Chair###Professor of Hematology Erasmus MC, dept. of Hematology and President of EMN###EMN###
Co-Chair: Pieter Sonneveld, MD, PhD (he/him/his) – EMN
### he/him/his @@@ Nikhil Munshi, MD – Dana-Farber Cancer Institute, Harvard Medical School ### 1395035###Co-Chair###Kraft Family Chair, Director of Basic and Correlative Science, Professor of Medicine, Harvard Medical School ###Dana-Farber Cancer Institute, Harvard Medical School###
Co-Chair: Nikhil Munshi, MD – Dana-Farber Cancer Institute, Harvard Medical School
###
Epigenetic drivers of disease progression

Felipe Prosper, MD (he/him/his) – Clinica Universidad de Navarra ### 1954261###Speaker###Director of Hematology and Cell Therapy Department###Clinica Universidad de Navarra###
Speaker: Felipe Prosper, MD (he/him/his) – Clinica Universidad de Navarra
### he/him/his
F
Failure of immune surveillance and disease evolution

Madhav V. Dhodapkar, MD, MBBS (he/him/his) – Winship Cancer Institute, Emory University, Atlanta, GA, USA ### 1395037###Speaker###Director, Center for Cancer Immunology###Winship Cancer Institute, Emory University, Atlanta, GA, USA###
Speaker: Madhav V. Dhodapkar, MD, MBBS (he/him/his) – Winship Cancer Institute, Emory University, Atlanta, GA, USA
### he/him/his
Finding the Optimal Fit Post Lenalidomide

Fredrik Schjesvold, MD, PhD – Oslo Myeloma Center, Department of Hematology, Oslo University Hospital and KG Jebsen Center for B Cell Malignancies, University of Oslo ### 1395054###Speaker###Head of Oslo Myeloma Center###Oslo Myeloma Center, Department of Hematology, Oslo University Hospital and KG Jebsen Center for B Cell Malignancies, University of Oslo###
Speaker: Fredrik Schjesvold, MD, PhD – Oslo Myeloma Center, Department of Hematology, Oslo University Hospital and KG Jebsen Center for B Cell Malignancies, University of Oslo
###
Fireside Chat

S. Vincent Rajkumar, MD – Mayo Clinic ### 1949877###Speaker###Edward W. and Betty Knight Scripps Professor of Medicine###Mayo Clinic###
Speaker: S. Vincent Rajkumar, MD – Mayo Clinic
### @@@ Siddhartha Mukherjee ### 1957007###Speaker#########
Speaker: Siddhartha Mukherjee
### @@@ Sagar Lonial, MD, FACP – Emory University School of Medicine, Atlanta, GA, USA ### 1395113###Speaker###Professor and Chair###Emory University School of Medicine, Atlanta, GA, USA###
Speaker: Sagar Lonial, MD, FACP – Emory University School of Medicine, Atlanta, GA, USA
###
H
How do we sequence CART, bispecifics and ADC and other drugs?

Niels van de Donk, MD PhD (he/him/his) – Amsterdam UMC ### 1949889###Speaker###professor###Amsterdam UMC###
Speaker: Niels van de Donk, MD PhD (he/him/his) – Amsterdam UMC
### he/him/his
How should we define refractoriness in myeloma?

Nizar J. Bahlis, MD – Arnie Charbonneau Cancer Institute - University of Calgary ### 1395112###Speaker###Associate Professor of Medicine - Hematology and Bone Marrow Transplantation###Arnie Charbonneau Cancer Institute - University of Calgary###
Speaker: Nizar J. Bahlis, MD – Arnie Charbonneau Cancer Institute - University of Calgary
###
I
Immune Profiling and Cellular Therapies

Bruno Paiva, PhD – Clínica Universidad de Navarra (CUN), Centro de Investigación Médica Aplicada (CIMA LAB Diagnostics), IDISNA, CIBERONC ### 1395051###Speaker###Director Flow Cytometry Core###Clínica Universidad de Navarra (CUN), Centro de Investigación Médica Aplicada (CIMA LAB Diagnostics), IDISNA, CIBERONC###
Speaker: Bruno Paiva, PhD – Clínica Universidad de Navarra (CUN), Centro de Investigación Médica Aplicada (CIMA LAB Diagnostics), IDISNA, CIBERONC
###
Immune-Based Strategies for Improving Outcomes

Rakesh Popat, MD, PhD – University College London Hospitals NHS Foundation Trust ### 1441806###Speaker###Consultant Haematologist & Associate Professor###University College London Hospitals NHS Foundation Trust###
Speaker: Rakesh Popat, MD, PhD – University College London Hospitals NHS Foundation Trust
###
Improving outcomes for all: addressing disparities

Rebecca Lu, MSN, FNP-C – MD Anderson ### 2011724###Speaker###Nurse Practitioner###MD Anderson###
Speaker: Rebecca Lu, MSN, FNP-C – MD Anderson
###
Improving quality of life: diet, exercise and lifestyle considerations

Urvi A. Shah, MD (she/her/hers) – Myeloma Service, Memorial Sloan Kettering Cancer Center ### 1443416###Speaker###Assistant Attending###Myeloma Service, Memorial Sloan Kettering Cancer Center###
Speaker: Urvi A. Shah, MD (she/her/hers) – Myeloma Service, Memorial Sloan Kettering Cancer Center
### she/her/hers
IMS Awards
Increasing heterogeneity of the aging MM patient population: diagnostic challenges

Alessandra Larocca, MD, PhD – University of Torino ### 1395053###Speaker###Associate Professor###University of Torino###
Speaker: Alessandra Larocca, MD, PhD – University of Torino
###
Industry Symposium Supported by Bristol Myers Squibb: Harnessing the Immune System Before and After CAR T Cell Therapies
Industry Symposium Supported by GSK: Current Issues in Multiple Myeloma: Management of the Aging Population

Paul G. Richardson, MD – Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA ### 1441820###Chair###Clinical Program Leader and Director of Clinical Research###Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA###
Chair: Paul G. Richardson, MD – Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
###
Industry Symposium Supported by Janssen: A new frontier? Redirecting treatment strategies in MM

Michel Delforge, MD/Phd – University of Leuven, Leuven, Belgium ### 1395153###Chair###Professor of Medicine###University of Leuven, Leuven, Belgium###
Chair: Michel Delforge, MD/Phd – University of Leuven, Leuven, Belgium
###
Industry Symposium Supported by Sanofi: Tailoring Treatment Strategies in the Modern Myeloma Landscape

Joseph Mikhael, MD – Translational Genomics Research Institute (TGen), City of Hope Cancer Center ### 1409001###Chair###Professor in Applied Cancer Research and Drug Discovery###Translational Genomics Research Institute (TGen), City of Hope Cancer Center###
Chair: Joseph Mikhael, MD – Translational Genomics Research Institute (TGen), City of Hope Cancer Center
###
Integrating T cell redirection in frontline MM

Adam D Cohen, MD – Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA ### 1441829###Speaker###Director of Myeloma Immunotherapy###Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA###
Speaker: Adam D Cohen, MD – Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
###
Introduction and housekeeping

Michel Delforge, MD/Phd – University of Leuven, Leuven, Belgium ### 1395153###Chair###Professor of Medicine###University of Leuven, Leuven, Belgium###
Chair: Michel Delforge, MD/Phd – University of Leuven, Leuven, Belgium
###
Is there a role for screening in monoclonal gammopathies?

Sigurdur Y. Kristinsson, MD, PhD – University of Iceland ### 1949875###Speaker###Professor of Hematology###University of Iceland###
Speaker: Sigurdur Y. Kristinsson, MD, PhD – University of Iceland
###
K
Keynote: Somatic mutations in normal tissues

Peter Campbell – The Wellcome Trust Sanger Inst ### 2082019###Speaker###Head of CASM###The Wellcome Trust Sanger Inst###
Speaker: Peter Campbell – The Wellcome Trust Sanger Inst
###
L
Liquid biopsy in myeloma to inform outcome and treatment decisions

Jens Lohr, MD, PhD – Dana-Farber Cancer Institute ### 1395128###Speaker###Assistant Professor###Dana-Farber Cancer Institute###
Speaker: Jens Lohr, MD, PhD – Dana-Farber Cancer Institute
###
M
Management of EMD and plasma cell leukemia

Laura Rosinol, MD, PhD (she/her/hers) – Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain ### 1395063###Speaker###Amyloidosis and Myeloma Unit, Department of Hematology###Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain###
Speaker: Laura Rosinol, MD, PhD (she/her/hers) – Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain
### she/her/hers
Managing acute immunotherapy complications

Krina K. Patel, MD (she/her/hers) – MD Anderson Cancer Center, University of Texas, Houston, TX, USA ### 1395098###Speaker###Associate Professor###MD Anderson Cancer Center, University of Texas, Houston, TX, USA###
Speaker: Krina K. Patel, MD (she/her/hers) – MD Anderson Cancer Center, University of Texas, Houston, TX, USA
### she/her/hers
Managing CAR T Cell Therapies in the Real World

Yi Lin, MD, PHD – Mayo Clinic, Rochester, MN, USA ### 1395155###Speaker###Associate Professor###Mayo Clinic, Rochester, MN, USA###
Speaker: Yi Lin, MD, PHD – Mayo Clinic, Rochester, MN, USA
###
Managing the older, frail patient with multiple co-morbidities

Salomon Manier, MD, PhD – Centre Hospitalier Universitaire de Lille, Université de Lille, Lille, France ### 1395123###Speaker###Professor of Medicine###Centre Hospitalier Universitaire de Lille, Université de Lille, Lille, France###
Speaker: Salomon Manier, MD, PhD – Centre Hospitalier Universitaire de Lille, Université de Lille, Lille, France
###
Meet the Professor: Approaches to MRD assessment

Ajay K. Nooka, MD, MPH (he/him/his) – Winship Cancer Institute, Emory University School of Medicine ### 1395064###Speaker###Professor, Department of Hematology and Medical Oncology###Winship Cancer Institute, Emory University School of Medicine###
Speaker: Ajay K. Nooka, MD, MPH (he/him/his) – Winship Cancer Institute, Emory University School of Medicine
### he/him/his @@@ Suzanne Trudel, MD – Princess Margaret Cancer Centre, Toronto, ON, Canada ### 1395092###Speaker###Professor of Medicine###Princess Margaret Cancer Centre, Toronto, ON, Canada###
Speaker: Suzanne Trudel, MD – Princess Margaret Cancer Centre, Toronto, ON, Canada
###
Meet the Professor: Artificial intelligence in myeloma: what would its utility be?

Marta Sonia González, MD (she/her/hers) – H CLINICO UNIVERSITARIO SANTIAGO DE COMPOSTELA ### 1954269###Speaker###HEMATOLOGIST###H CLINICO UNIVERSITARIO SANTIAGO DE COMPOSTELA###
Speaker: Marta Sonia González, MD (she/her/hers) – H CLINICO UNIVERSITARIO SANTIAGO DE COMPOSTELA
### she/her/hers @@@ Claudio Cerchione, MD, PhD (he/him/his) – Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy ### 1661147###Speaker###Clinician###Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy###
Speaker: Claudio Cerchione, MD, PhD (he/him/his) – Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
### he/him/his
Meet the Professor: Assessing QOL and PRO measures

Tanya Wildes, MD, MSCI (she/her/hers) – University of Nebraska Medical Center/Nebraska Medicine ### 1954266###Speaker###Associate Professor of Medicine###University of Nebraska Medical Center/Nebraska Medicine###
Speaker: Tanya Wildes, MD, MSCI (she/her/hers) – University of Nebraska Medical Center/Nebraska Medicine
### she/her/hers @@@ Raphael Szalat, MD; PhD (he/him/his) – Boston University Chobanian & Avedisian School of Medicine ### 1442373###Speaker###Assistant professor of Medicine###Boston University Chobanian & Avedisian School of Medicine###
Speaker: Raphael Szalat, MD; PhD (he/him/his) – Boston University Chobanian & Avedisian School of Medicine
### he/him/his
Meet the Professor: Castlemans and POEMS

Angela Dispenzieri, MD – Mayo Clinic Rochester ### 1395071###Speaker###Professor, Division of Hematology, Department of Internal Medicine###Mayo Clinic Rochester###
Speaker: Angela Dispenzieri, MD – Mayo Clinic Rochester
### @@@ Frits van Rhee, MD PHD (he/him/his) – Myeloma Center, University of Arkansas of Medicine ### 1954268###Speaker###Professor of Medicine###Myeloma Center, University of Arkansas of Medicine###
Speaker: Frits van Rhee, MD PHD (he/him/his) – Myeloma Center, University of Arkansas of Medicine
### he/him/his
Meet the Professor: Clonal hematopoiesis in myeloma: implications for therapy

Enrique M. Ocio, MD, PhD – Hospital Universitario Marqués de Valdecilla (IDIVAL), Santander, Spain ### 1409099###Speaker###Head of the Hematology Department###Hospital Universitario Marqués de Valdecilla (IDIVAL), Santander, Spain###
Speaker: Enrique M. Ocio, MD, PhD – Hospital Universitario Marqués de Valdecilla (IDIVAL), Santander, Spain
### @@@ Adam S. Sperling, MD, PhD (he/him/his) – Brigham and Women's Hospital ### 1395133###Speaker###Assistant Professor###Brigham and Women's Hospital###
Speaker: Adam S. Sperling, MD, PhD (he/him/his) – Brigham and Women's Hospital
### he/him/his
Meet the Professor: Diagnostic approach to a monoclonal protein (lab-based)

Dave Murray, MD PhD – Mayo Clinic ### 1395052###Speaker###Consultant###Mayo Clinic###
Speaker: Dave Murray, MD PhD – Mayo Clinic
### @@@ Joan Bladé, MD PhD – Amyloidosis and Myeloma Unit. Hospital Clínic de Barcelona. IDIBAPS. University of Barcelona. Barcelona, Spain ### 1441772###Speaker###Hematologist###Amyloidosis and Myeloma Unit. Hospital Clínic de Barcelona. IDIBAPS. University of Barcelona. Barcelona, Spain###
Speaker: Joan Bladé, MD PhD – Amyloidosis and Myeloma Unit. Hospital Clínic de Barcelona. IDIBAPS. University of Barcelona. Barcelona, Spain
###
Meet the Professor: Laboratory assessment of immune function

David Avigan, MD (he/him/his) – Beth Israel Deaconess Medical Center ### 1395158###Speaker###Chief, Division of Hematology and Hematologic Malignancies; Cancer Center Director, Beth Israel Deaconess Medical Center; Senior Vice President of Cancer Service, Beth Israel Lahey Health ###Beth Israel Deaconess Medical Center###
Speaker: David Avigan, MD (he/him/his) – Beth Israel Deaconess Medical Center
### he/him/his @@@ Heinz Ludwig, MD – Department of Medicine I, Wilhelminen Cancer Research Institute, Klinik Ottakring ### 1442243###Speaker###Head of Institute###Department of Medicine I, Wilhelminen Cancer Research Institute, Klinik Ottakring###
Speaker: Heinz Ludwig, MD – Department of Medicine I, Wilhelminen Cancer Research Institute, Klinik Ottakring
###
Meet the Professor: Light chain amyloidosis

Ashutosh D. Wechalekar, MD – University College Hospital ### 1441901###Speaker###Professor of Medicine and Haematology###University College Hospital###
Speaker: Ashutosh D. Wechalekar, MD – University College Hospital
### @@@ Vaishali Sanchorawala, MD (she/her/hers) – Boston University Chobanian & Avedisian School of Medicine ### 1395067###Speaker###Director, Amyloidosis Center,### Boston University Chobanian & Avedisian School of Medicine###
Speaker: Vaishali Sanchorawala, MD (she/her/hers) – Boston University Chobanian & Avedisian School of Medicine
### she/her/hers
Meet the Professor: Management of bone disease

Andrew J. Yee, MD – Massachusetts General Hospital Cancer Center ### 1442036###Speaker###Clinical Director, Center for Multiple Myeloma###Massachusetts General Hospital Cancer Center###
Speaker: Andrew J. Yee, MD – Massachusetts General Hospital Cancer Center
###
Meet the Professor: Managing renal failure in MM

Efstathios Kastritis, MD, PhD (he/him/his) – National and Kapodistrian University of Athens ### 1949897###Speaker###Professor of Medicine ###National and Kapodistrian University of Athens ###
Speaker: Efstathios Kastritis, MD, PhD (he/him/his) – National and Kapodistrian University of Athens
### he/him/his @@@ Pankaj Malhorta, MD – Postgraduate Institute of Medical Education and Research ### 1949879###Speaker###Professor and Head###Postgraduate Institute of Medical Education and Research###
Speaker: Pankaj Malhorta, MD – Postgraduate Institute of Medical Education and Research
###
Meet the Professor: Neuropathy and MGUS

Jorge J. Castillo, MD (he/him/his) – Dana-Farber Cancer Institute ### 1416879###Speaker###Associate Professor of Medicine###Dana-Farber Cancer Institute###
Speaker: Jorge J. Castillo, MD (he/him/his) – Dana-Farber Cancer Institute
### he/him/his @@@ Andrew R. Branagan, MD, PhD – Massachusetts General Hospital ### 1442194###Speaker###Attending Physician###Massachusetts General Hospital###
Speaker: Andrew R. Branagan, MD, PhD – Massachusetts General Hospital
###
Meet the Professor: Optimal imaging approaches in MM

Elena Zamagni, Sr., MD, PhD (she/her/hers) – European Myeloma Network, Italy ### 1395050###Speaker###Investigator###European Myeloma Network, Italy###
Speaker: Elena Zamagni, Sr., MD, PhD (she/her/hers) – European Myeloma Network, Italy
### she/her/hers @@@ Jens Hillengass, MD, PhD – Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA ### 1409085###Speaker###Professor of Oncology and Internal Medicine###Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA###
Speaker: Jens Hillengass, MD, PhD – Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
###
Meet the Professor: Optimizing in vitro cellular models of MM

Mariateresa Fulciniti, PhD – Dana Farber Cancer Institute ### 1949886###Speaker###Lead Scientist###Dana Farber Cancer Institute###
Speaker: Mariateresa Fulciniti, PhD – Dana Farber Cancer Institute
### @@@ Niccolo Bolli, Prof. – University of Milan ### 1949887###Speaker###Associate Professor of Hematology###University of Milan###
Speaker: Niccolo Bolli, Prof. – University of Milan
###
Meet the Professor: Proteomic evaluation in MM

Constantine S. Mitsiades, MD, PhD – Dana Farber Cancer Institute ### 1409098###Speaker###Associate Professor in Medicine###Dana Farber Cancer Institute###
Speaker: Constantine S. Mitsiades, MD, PhD – Dana Farber Cancer Institute
### @@@ Manoj Bhasin, PhD – Emory University ### 1395127###Speaker###Director of Genomics, Proteomics, Bioinformatics and Systems Biology at Children’s Healthcare of Atlanta. ###Emory University###
Speaker: Manoj Bhasin, PhD – Emory University
###
Meet the Professor: Racial disparity: impact and solutions

Lalit Kumar, MD, DM (he/him/his) – Oncology and BMT, Artemis Hospitals, Gurugram122001, India ### 1443208###Speaker###Chairperson###Oncology and BMT, Artemis Hospitals, Gurugram122001, India###
Speaker: Lalit Kumar, MD, DM (he/him/his) – Oncology and BMT, Artemis Hospitals, Gurugram122001, India
### he/him/his @@@ Craig E. Cole, MD – Michigan State University-Karmanos Cancer Institute ### 1395102###Speaker###Assistant Professor###Michigan State University-Karmanos Cancer Institute###
Speaker: Craig E. Cole, MD – Michigan State University-Karmanos Cancer Institute
###
Meet the Professor: Risk stratified follow up of MGUS and SMM

Meral Beksac, MD (she/her/hers) – Ankara University ### 1443293###Speaker###Professor of Hematology###Ankara University###
Speaker: Meral Beksac, MD (she/her/hers) – Ankara University
### she/her/hers @@@ Natalie Callander, MD – University of Wisconsin ### 1949893###Speaker###Director, Myeloma Clinical Program###University of Wisconsin###
Speaker: Natalie Callander, MD – University of Wisconsin
###
Meet the Professor: Single cell genomic techniques for study of myeloma

Samir Parekh, MD – Mount Sinai Medical Center, New York, NY, USA ### 1441821###Speaker###Professor of Medicine, Hematology-Oncology & Oncological Sciences###Mount Sinai Medical Center, New York, NY, USA###
Speaker: Samir Parekh, MD – Mount Sinai Medical Center, New York, NY, USA
### @@@ Brian A. Walker, PhD (he/him/his) – Indiana University ### 1395036###Speaker###Professor###Indiana University###
Speaker: Brian A. Walker, PhD (he/him/his) – Indiana University
### he/him/his
Meet the Professor: Solitary tumor plasmacytoma

Carlos Fernandez de Larrea, MD, PhD – Hospital Clínic de Barcelona ### 1949895###Speaker###Consultant, Amyloidosis and Myeloma Unit, Department of Hematology###Hospital Clínic de Barcelona###
Speaker: Carlos Fernandez de Larrea, MD, PhD – Hospital Clínic de Barcelona
### @@@ Andrzej J. Jakubowiak, MD, PhD – University of Chicago, Chicago, IL, USA ### 1409087###Speaker###Professor of Medicine; Director, Myeloma Program###University of Chicago, Chicago, IL, USA###
Speaker: Andrzej J. Jakubowiak, MD, PhD – University of Chicago, Chicago, IL, USA
###
Meet the Professor: Understanding the concept of MGRS

Nelson Leung, MD – Division of hematology and Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN ### 1395109###Speaker###Consultant###Division of hematology and Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN###
Speaker: Nelson Leung, MD – Division of hematology and Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN
###
Meet the Professor: Vaccination and infection prevention

Karthik Ramasamy, MBBS FRCP FRCPath PhD – University of Oxford and Oxford University Hospitals NHS FT ### 1949894###Speaker###Associate Professor & Consultant Haematologist###University of Oxford and Oxford University Hospitals NHS FT###
Speaker: Karthik Ramasamy, MBBS FRCP FRCPath PhD – University of Oxford and Oxford University Hospitals NHS FT
### @@@ Dorotea Fantl, MD – Hospital Italiano de Buenos Aires, Argentina. ### 1409082###Speaker###Consultant Physician in the Hematology Department of the Hospital Italiano de Buenos Aires ###Hospital Italiano de Buenos Aires, Argentina.###
Speaker: Dorotea Fantl, MD – Hospital Italiano de Buenos Aires, Argentina.
###
Meet the Professor: Waldenstrom macroglobulinemia

Prashant Kapoor, MD – Mayo Clinic ### 1395070###Speaker###Consultant/Associate Professor of Medicine ###Mayo Clinic###
Speaker: Prashant Kapoor, MD – Mayo Clinic
### @@@ Veronique Leblond, MD (she/her/hers) – Sorbonne Université ### 1954265###Speaker###Professeur emerite###Sorbonne Université ###
Speaker: Veronique Leblond, MD (she/her/hers) – Sorbonne Université
### she/her/hers
Metabolomic alterations defining disease progression in myeloma

Mala Shanmugam, MS, PhD (she/her/hers) – Winship Cancer Institute, Emory University ### 1395131###Speaker###Associate Professor###Winship Cancer Institute, Emory University###
Speaker: Mala Shanmugam, MS, PhD (she/her/hers) – Winship Cancer Institute, Emory University
### she/her/hers
Molecular characterization and therapeutic targeting of protein kinase D2 in T(414) multiple myeloma

Raphael Szalat, MD; PhD (he/him/his) – Boston University Chobanian & Avedisian School of Medicine ### 1442373###Speaker###Assistant professor of Medicine###Boston University Chobanian & Avedisian School of Medicine###
Speaker: Raphael Szalat, MD; PhD (he/him/his) – Boston University Chobanian & Avedisian School of Medicine
### he/him/his
Molecular determinants of drug resistance

Lawrence Boise, PhD (he/him/his) – Emory University ### 1949882###Speaker###Professor###Emory University###
Speaker: Lawrence Boise, PhD (he/him/his) – Emory University
### he/him/his
Molecular drivers of extramedullary progression

Moritz Binder, MD MPH (he/him/his) – Mayo Clinic ### 1718954###Speaker###Senior Associate Consultant###Mayo Clinic###
Speaker: Moritz Binder, MD MPH (he/him/his) – Mayo Clinic
### he/him/his
MRD and CLL

Paolo Ghia, MD. PhD (he/him/his) – Università Vita-Salute San Raffaele ### 2075353###Speaker###Professor of Medical Oncology###Università Vita-Salute San Raffaele###
Speaker: Paolo Ghia, MD. PhD (he/him/his) – Università Vita-Salute San Raffaele
### he/him/his
N
Newly Diagnosed Multiple Myeloma

Maria-Victoria Mateos, PhD (she/her/hers) – University Hospital of Salamanca ### 1949876###Chair###Head of Unit###University Hospital of Salamanca###
Chair: Maria-Victoria Mateos, PhD (she/her/hers) – University Hospital of Salamanca
### she/her/hers @@@ S. Vincent Rajkumar, MD – Mayo Clinic ### 1949877###Co-Chair###Edward W. and Betty Knight Scripps Professor of Medicine###Mayo Clinic###
Co-Chair: S. Vincent Rajkumar, MD – Mayo Clinic
###
Non-Immune therapy for TCR

Paula Rodriguez-Otero, MD PhD (she/her/hers) – Clinica Universidad de Navarra ### 1949883###Speaker###Consultant in Hematology ###Clinica Universidad de Navarra ###
Speaker: Paula Rodriguez-Otero, MD PhD (she/her/hers) – Clinica Universidad de Navarra
### she/her/hers
Novel in vivo models of myeloma origin

Karin Vanderkerken, PhD (she/her/hers) – Vrije Universiteit Brusssels ### 1949874###Speaker###full professor###Vrije Universiteit Brusssels###
Speaker: Karin Vanderkerken, PhD (she/her/hers) – Vrije Universiteit Brusssels
### she/her/hers
Novel Technology and Insights in MM

Kenneth C. Anderson, MD – The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA ### 1395077###Chair###Professor in Medicine###The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA###
Chair: Kenneth C. Anderson, MD – The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
### @@@ Gareth Morgan, MD, PHD, FRCP, FRCPATH (he/him/his) – NYU Langone Health Perlmutter Cancer Center ### 1395144###Co-Chair###Professor of Medicine, Director of Myeloma Research###NYU Langone Health Perlmutter Cancer Center###
Co-Chair: Gareth Morgan, MD, PHD, FRCP, FRCPATH (he/him/his) – NYU Langone Health Perlmutter Cancer Center
### he/him/his
NSO-01: Real world experience of teclistamab using a prompt management strategy for cytokine release syndrome

Donna D. Catamero, ANP-BC – Mount Sinai Hospital ### 1442247###Speaker###Nurse Practitioner###Mount Sinai Hospital###
Speaker: Donna D. Catamero, ANP-BC – Mount Sinai Hospital
###
NSO-02: Characteristics of Multiple Myeloma Patients with Central Nervous System Involvement

Jessica Chen, MS, FNP – MD Anderson Cancer Center ### 2076077###Speaker###Nurse Practitioner###MD Anderson Cancer Center###
Speaker: Jessica Chen, MS, FNP – MD Anderson Cancer Center
###
NSO-03: Impact of Myeloma and Amyloidosis on young patients

Emma Dowling, RN BSC – HCA Healthcare UK ### 1442039###Speaker###Myeloma Clinical nurse specialist###HCA Healthcare UK###
Speaker: Emma Dowling, RN BSC – HCA Healthcare UK
###
NSO-04: Characterising sleep disturbances with actigraphy in those receiving steroids for the treatment of multiple myeloma: Findings from a pilot study

Tracy King, PhD, MN, RN – Royal Prince Alfred Hospital, The University of Sydney ### 1408995###Speaker###Myeloma Nurse Consultant, Clinical Associate Professor###Royal Prince Alfred Hospital, The University of Sydney###
Speaker: Tracy King, PhD, MN, RN – Royal Prince Alfred Hospital, The University of Sydney
###
NSO-05: Specialist physiotherapy post-autologous stem cell transplant improved functional outcomes with high patient satisfaction in multiple myeloma patients

Joanne S. Land, BSc (she/her/hers) – NHS University College London Hospital, London, United Kingdom ### 2076076###Speaker###Clinical Specialist Myeloma Physiotherapist###NHS University College London Hospital, London, United Kingdom###
Speaker: Joanne S. Land, BSc (she/her/hers) – NHS University College London Hospital, London, United Kingdom
### she/her/hers
NSO-06: ‘Just one thing’: patient, nurse and haematologist priorities for myeloma services

Monica Morris, MSc, RN – Myeloma UK ### 1408999###Speaker###Clinical Practice Services ###Myeloma UK###
Speaker: Monica Morris, MSc, RN – Myeloma UK
###
NSO-07: Management Considerations for Dermatologic Toxicities Associated With Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma

Chloe Ray, AGPCNP-BC, OCN – Mount Sinai Hospital ### 2082047###Speaker###Clinical Research Nurse Practitioner###Mount Sinai Hospital###
Speaker: Chloe Ray, AGPCNP-BC, OCN – Mount Sinai Hospital
###
O
OA-01: Exploiting microbiota commensals to potentiate immunotherapy and delay multiple myeloma evolution

Laura Lucia Cogrossi – San Raffaele Scientific Institute ### 2076066###Speaker###PhD Student###San Raffaele Scientific Institute###
Speaker: Laura Lucia Cogrossi – San Raffaele Scientific Institute
###
OA-02: α-NKG2A blockade overcomes multiple myeloma resistance to BCMA and NKG2D CAR-NKAE cells

Jessica Encinas Mayoral (she/her/hers) – Fundación Investigación Biomédica Hospital 12 de Octubre ### 1442692###Speaker###PhD student###Fundación Investigación Biomédica Hospital 12 de Octubre###
Speaker: Jessica Encinas Mayoral (she/her/hers) – Fundación Investigación Biomédica Hospital 12 de Octubre
### she/her/hers
OA-03: Bispecific T-cell engager response is driven by pre-treatment CD8+ effector memory cells and inhibited by TIGIT+ Tregs in relapsed/refractory multiple myeloma

Ross S. Firestone, MD/PhD (he/him/his) – Memorial Sloan Kettering Cancer Center, New York City NY, USA ### 2076051###Speaker###Fellow - Hematology / Oncology###Memorial Sloan Kettering Cancer Center, New York City NY, USA###
Speaker: Ross S. Firestone, MD/PhD (he/him/his) – Memorial Sloan Kettering Cancer Center, New York City NY, USA
### he/him/his
OA-04: Single cell multi-omic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma

Maximilian Merz, MD (he/him/his) – University of Leipzig ### 2131520###Speaker###Attending Physician###University of Leipzig###
Speaker: Maximilian Merz, MD (he/him/his) – University of Leipzig
### he/him/his
OA-05: Efficacy of forimtamig, a GPRC5DxCD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): analysis of patient- and disease-related factors associated with responses

Simon J. Harrison, MBBS, MRCP(uk), FRCPath(uk), FRACP, PhD (he/him/his) – Peter MacCallum Cancer Centre ### 1395103###Speaker###Director, Centre of Excellence in Cellular Immunotherapy###Peter MacCallum Cancer Centre###
Speaker: Simon J. Harrison, MBBS, MRCP(uk), FRCPath(uk), FRACP, PhD (he/him/his) – Peter MacCallum Cancer Centre
### he/him/his
OA-06: Robust in vivo expansion and long-term persistence of anti-BCMA CAR T cells, PHE885, manufactured in <2 days on the T-Charge platform

Shuntaro Ikegawa, MD, PhD – Dana-Farber Cancer Institute ### 2076071###Speaker###Research fellow###Dana-Farber Cancer Institute###
Speaker: Shuntaro Ikegawa, MD, PhD – Dana-Farber Cancer Institute
###
OA-07: Phase I Study of BCMA CAR-T Using Instant Manufacturing Platform or Traditional Production Process for Relapsed/Refractory Multiple Myeloma Therapy

Hui Liu, LH – Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, China ### 1443969###Speaker###Professor###Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, China###
Speaker: Hui Liu, LH – Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, China
###
OA-08: GPRC5D-Targeted CAR-T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma Progressing after or Refractory to BCMA CAR-T cell therapy: Updated Results from a Phase 2 Clinical Trial

Jieyun Xia, MD – The Affiliated Hospital of Xuzhou Medical University ### 2076072###Speaker###doctor###The Affiliated Hospital of Xuzhou Medical University###
Speaker: Jieyun Xia, MD – The Affiliated Hospital of Xuzhou Medical University
###
OA-09: Combination of forimtamig with standard of care improves depth and duration of response in preclinical models of multiple myeloma

Aintzane Zabaleta, PhD (she/her/hers) – CIMA (Pamplona) ### 2081759###Speaker###Research assistant###CIMA (Pamplona)###
Speaker: Aintzane Zabaleta, PhD (she/her/hers) – CIMA (Pamplona)
### she/her/hers
OA-10: Four years treatment with Zoledronic Acid is superior to two years in protection against progressive bone disease in Multiple Myeloma

Thomas Lund, MD, PhD (he/him/his) – Department of Hematology Odense University Hospital ### 1442963###Speaker###Associated Professor###Department of Hematology Odense University Hospital###
Speaker: Thomas Lund, MD, PhD (he/him/his) – Department of Hematology Odense University Hospital
### he/him/his
OA-11: Utility of 18FDG-PET/CT for Risk Prediction in Relapsed/Refractory Multiple Myeloma Patients Undergoing CAR-T Cell Therapy: Analysis of Baseline and Early Assessment Scans After One and Three Months

Luis-Esteban Tamariz-Amador, MD – Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IdiSNA ### 2076070###Speaker###MD###Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IdiSNA###
Speaker: Luis-Esteban Tamariz-Amador, MD – Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IdiSNA
###
OA-12: Predictors of unsustained measurable residual disease (MRD) negativity in transplant-eligible multiple myeloma (MM) patients

Camila Guerrero – Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16/12/00369 ### 1441952###Speaker###PhD Student###Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16/12/00369###
Speaker: Camila Guerrero – Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16/12/00369
###
OA-13: Increased levels of circulating tumor cells correlate with adverse clinical outcomes and distinct biological features in newly diagnosed patients with multiple myeloma

Ioannis V Kostopoulos, n/a – Section of Animal and Human Physiology, Department of Biology, School of Sciences, National and Kapodistrian University of Athens, Athens, Greece ### 2076059###Speaker###Post doctoral research fellow###Section of Animal and Human Physiology, Department of Biology, School of Sciences, National and Kapodistrian University of Athens, Athens, Greece###
Speaker: Ioannis V Kostopoulos, n/a – Section of Animal and Human Physiology, Department of Biology, School of Sciences, National and Kapodistrian University of Athens, Athens, Greece
###
OA-14: Persistent bone marrow and imaging MRD negativity may guide the duration of lenalidomide maintenance following ASCT in patients with multiple myeloma

Panagiotis Malandrakis, MD (he/him/his) – Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece ### 1442827###Speaker###Scientific associate###Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece###
Speaker: Panagiotis Malandrakis, MD (he/him/his) – Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
### he/him/his
OA-15: Serial MRD Assessments as a Surrogate for Long Term Progression Free Survival

Frits van Rhee, MD PHD (he/him/his) – Myeloma Center, University of Arkansas of Medicine ### 1954268###Speaker###Professor of Medicine###Myeloma Center, University of Arkansas of Medicine###
Speaker: Frits van Rhee, MD PHD (he/him/his) – Myeloma Center, University of Arkansas of Medicine
### he/him/his
OA-16: The rs9344 G risk allele upregulates CCND1 expression through t(11;14) and PAX5 in multiple myeloma

Linda B. Baughn, PhD (she/her/hers) – Mayo Clinic, Rochester, MN, US ### 2076266###Speaker###Co-director, Cytogenetics Laboratory/Consultant###Mayo Clinic, Rochester, MN, US###
Speaker: Linda B. Baughn, PhD (she/her/hers) – Mayo Clinic, Rochester, MN, US
### she/her/hers
OA-17: Tracking the earliest genomic events in multiple myeloma life-history

Anthony Cirrincione, PhD – Myeloma Service, Sylvester Comprehensive Cancer Center, University of Miami ### 2076061###Speaker###Postdoctoral Associate###Myeloma Service, Sylvester Comprehensive Cancer Center, University of Miami###
Speaker: Anthony Cirrincione, PhD – Myeloma Service, Sylvester Comprehensive Cancer Center, University of Miami
###
OA-18: Identification of therapy-induced clonal evolution and resistance pathways in MRD clones in multiple myeloma through single-cell sequencing

Jian Cui – Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College ### 1719009###Speaker###postgraduate###Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College###
Speaker: Jian Cui – Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College
###
OA-19: Comprehensive genomic characterization of response and resistance to daratumumab- based quadruplet induction in newly diagnosed multiple myeloma patients

Kylee Maclachlan, MBChB, PhD – Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City NY, USA ### 1443581###Speaker###Assistant Attending Physician###Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City NY, USA###
Speaker: Kylee Maclachlan, MBChB, PhD – Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City NY, USA
###
OA-20: Genomic profiling of high-risk smoldering myeloma patients treated with a curative strategy: a biological study of the phase II GEM CESAR clinical trial.

Alejandro Medina-Herrera, PhD – Departamento de Hematología, Hospital Universitario de Salamanca, (HUSA/IBSAL), Centro de Investigación del Cáncer-IBMCC (CSIC/USAL), CIBERONC ### 2076068###Speaker###Postdoctoral researcher###Departamento de Hematología, Hospital Universitario de Salamanca, (HUSA/IBSAL), Centro de Investigación del Cáncer-IBMCC (CSIC/USAL), CIBERONC###
Speaker: Alejandro Medina-Herrera, PhD – Departamento de Hematología, Hospital Universitario de Salamanca, (HUSA/IBSAL), Centro de Investigación del Cáncer-IBMCC (CSIC/USAL), CIBERONC
###
OA-21: Dysregulated APOBEC3B promotes cell proliferation and DNA damage in multiple myeloma

Afsaneh Panahi, MSc – BC Cancer Research Centre/ University of British Columbia ### 2076074###Speaker###PhD candidate###BC Cancer Research Centre/ University of British Columbia###
Speaker: Afsaneh Panahi, MSc – BC Cancer Research Centre/ University of British Columbia
###
OA-22: TiMMing: Developing an Innovative Suite of Bioinformatic Tools to Harmonize and Track the Origin of Copy Number Alterations in the Evolutionary History of Multiple Myeloma

Andrea Poletti, PhD – IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli” - Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy ### 1441986###Speaker###Bioinformatician###IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli” - Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy###
Speaker: Andrea Poletti, PhD – IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli” - Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy
###
OA-23: Resolving therapy resistance mechanisms in multiple myeloma by multi-omics subclone analysis

Alexandra M. Poos, PhD (she/her/hers) – Multiple Myeloma Section, Department of Medicine V, University Hospital Heidelberg ### 1442081###Speaker###PostDoc###Multiple Myeloma Section, Department of Medicine V, University Hospital Heidelberg###
Speaker: Alexandra M. Poos, PhD (she/her/hers) – Multiple Myeloma Section, Department of Medicine V, University Hospital Heidelberg
### she/her/hers
OA-24: Sequential and persistent loss of BCMA and GPRC5D after bispecific antibodies in multiple myeloma revealed by whole genome sequencing

Leo Rasche, MD – Department of Internal Medicine II, University Hospital, 97080 Würzburg, Germany ### 1442365###Speaker###associate professor###Department of Internal Medicine II, University Hospital, 97080 Würzburg, Germany###
Speaker: Leo Rasche, MD – Department of Internal Medicine II, University Hospital, 97080 Würzburg, Germany
###
OA-25: MM B cells and pre-plasma cell progenitors are the cellular origin of MM disease relapse following effective therapy targeting plasma cells

Rodger E. Tiedemann, MD, PhD (he/him/his) – Princess Margaret Cancer Centre ### 1395134###Speaker###Senior Scientist, Hematologist###Princess Margaret Cancer Centre###
Speaker: Rodger E. Tiedemann, MD, PhD (he/him/his) – Princess Margaret Cancer Centre
### he/him/his
OA-26: Single-cell analysis reveals disease induced perturbations of monocytes in the bone marrow and peripheral blood of multiple myeloma patients

Jian Cui – Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College ### 1719009###Speaker###postgraduate###Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College###
Speaker: Jian Cui – Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College
###
OA-27: Single cell transcriptomics reveals the impact of tumor cell interactions with the bone marrow immune microenvironment in the progression of multiple myeloma

Parvathi Sudha, MS (she/her/hers) – Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology and Oncology, School of Medicine, Indiana University, Indianapolis, IN, USA ### 2076063###Speaker###Research Associate###Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology and Oncology, School of Medicine, Indiana University, Indianapolis, IN, USA###
Speaker: Parvathi Sudha, MS (she/her/hers) – Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology and Oncology, School of Medicine, Indiana University, Indianapolis, IN, USA
### she/her/hers
OA-28: Unraveling the heterogeneity of multiple myeloma associated with therapy resistance by single-cell RNA sequencing

Takahiro Kamiya, MD (he/him/his) – Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan / Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan ### 2076050###Speaker###Graduate student###Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan / Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan###
Speaker: Takahiro Kamiya, MD (he/him/his) – Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan / Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
### he/him/his
OA-29: First Results From the Randomized Portion of a Phase 2 Study of Venetoclax Plus Carfilzomib-Dexamethasone vs Carfilzomib-Dexamethasone in Patients With t(11;14) Relapsed/Refractory Multiple Myeloma

Jonathan L. Kaufman, MD – Winship Cancer Institute of Emory University ### 1395159###Speaker###Professor of Hematology and Medical Oncology###Winship Cancer Institute of Emory University###
Speaker: Jonathan L. Kaufman, MD – Winship Cancer Institute of Emory University
###
OA-30: Critical roles of CRIP1 in promoting cell survival and bortezomib resistance by enhancing proteasome activity and autophagy in multiple myeloma

Hao Mu, Principle Investigation (she/her/hers) – State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China. ### 1442108###Speaker###Professor###State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China.###
Speaker: Hao Mu, Principle Investigation (she/her/hers) – State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China.
### she/her/hers
OA-31: Efficacy of Bispecific Antibodies in the Treatment of Extramedullary disease and High risk cytogenetics in Relapsed Multiple Myeloma: A Systematic Review

Charan T R Vegivinti, MD (he/him/his) – Jacobi Medical Center / Albert Einstein College of Medicine ### 2076065###Speaker###Internal Medicine Resident###Jacobi Medical Center / Albert Einstein College of Medicine###
Speaker: Charan T R Vegivinti, MD (he/him/his) – Jacobi Medical Center / Albert Einstein College of Medicine
### he/him/his
OA-32: The Impact of Genomics to Identify Novel Immunotherapeutic Targets in Multiple Myeloma

Brian A. Walker, PhD (he/him/his) – Indiana University ### 1395036###Speaker###Professor###Indiana University###
Speaker: Brian A. Walker, PhD (he/him/his) – Indiana University
### he/him/his
OA-33: Aberrant B cell differentiation induce plasma cell malignancy

Wen Zhou, PhD – Cancer Research Institute, Xiangya School of Medicine, Central South University ### 2076970###Speaker###Xiangya Road110# Changsha, Hunan Province, China###Cancer Research Institute, Xiangya School of Medicine, Central South University###
Speaker: Wen Zhou, PhD – Cancer Research Institute, Xiangya School of Medicine, Central South University
###
OA-34: Feasibility of a novel academic anti-BCMA chimeric antigen receptor T-cell (CART) (HBI0101) for the treatment of relapsed and refractory AL amyloidosis

Eyal Lebel, MD – Hadassah medical center ### 2076057###Speaker###Senior Physician and researcher###Hadassah medical center###
Speaker: Eyal Lebel, MD – Hadassah medical center
###
OA-35: High-throughput plasma proteomics to define the precursor multiple myeloma proteome and identify candidate high-risk disease biomarkers of progression

Elizabeth D. Lightbody, PhD – Dana-Farber Cancer Institute ### 2076073###Speaker###Instructor in Medicine###Dana-Farber Cancer Institute###
Speaker: Elizabeth D. Lightbody, PhD – Dana-Farber Cancer Institute
###
OA-36: sBCMA predicts progression and is a biomarker of response in myeloma precursor disease followed on prospective studies

wei tan, Ph.D – The University of Texas MD Anderson Cancer Center ### 2076054###Speaker###Research Scientist###The University of Texas MD Anderson Cancer Center###
Speaker: wei tan, Ph.D – The University of Texas MD Anderson Cancer Center
###
OA-37: Optimization of the 20/2/20 risk stratification model for patients with smoldering multiple myeloma through integration of the evolving patterns of monoclonal protein and serum free light chains

Annika Werly – Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany ### 2076067###Speaker###Doctoral student###Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany###
Speaker: Annika Werly – Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany
###
OA-38: Physical activity interventions to improve functional performance in patients with multiple myeloma

Jens Hillengass, MD, PhD – Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA ### 1409085###Speaker###Professor of Oncology and Internal Medicine###Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA###
Speaker: Jens Hillengass, MD, PhD – Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
###
OA-39: Development and Validation of a Prognostic Survival Model with Patient Reported Outcomes for Older Adults with Multiple Myeloma

Hira Mian, MD, MSc, FRCPC – McMaster University, Hamilton, Ontario, Canada ### 1719006###Speaker###Assistant Professor###McMaster University, Hamilton, Ontario, Canada###
Speaker: Hira Mian, MD, MSc, FRCPC – McMaster University, Hamilton, Ontario, Canada
###
OA-40: Frailty and initial treatment intensity in patients newly diagnosed with multiple myeloma

Clark DuMontier, MD, MPH (he/him/his) – VA Boston Healthcare System and Brigham and Women's Hospital/Harvard Medical School ### 2076053###Speaker###Geriatrician, Assistant Professor###VA Boston Healthcare System and Brigham and Women's Hospital/Harvard Medical School###
Speaker: Clark DuMontier, MD, MPH (he/him/his) – VA Boston Healthcare System and Brigham and Women's Hospital/Harvard Medical School
### he/him/his
OA-41: Iberdomide, bortezomib, and dexamethasone (IberVd) in transplant-ineligible newly diagnosed multiple myeloma (NDMM): results from the CC-220-MM-001 trial

Darrell White, MD (he/him/his) – Dalhousie University and Queen Elizabeth II Health Sciences Centre ### 1443022###Speaker###Hematologist, Senior Associate Dean###Dalhousie University and Queen Elizabeth II Health Sciences Centre###
Speaker: Darrell White, MD (he/him/his) – Dalhousie University and Queen Elizabeth II Health Sciences Centre
### he/him/his
OA-42: Second Primary Malignancies after Tandem Autologous Hematopoietic Stem Cell Transplantation for patients with Multiple Myeloma Treated on Earlier Total Therapy Protocols

Samer Al Hadidi, MD,MS,FACP – the University of Arkansas for Medical Sciences ### 1719063###Speaker###Assistant Professor###the University of Arkansas for Medical Sciences###
Speaker: Samer Al Hadidi, MD,MS,FACP – the University of Arkansas for Medical Sciences
###
OA-43: Analysis of sustained MRD-negativity and Progression-free Survival of Isa-KRd in High-Risk Newly Diagnosed Multiple Myeloma – Additional Data from Planned Interim Analysis of the GMMG-CONCEPT Trial

Lisa B. Leypoldt, MD (she/her/hers) – University Medical Center Hamburg-Eppendorf, Germany / Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Department of Medicine, Harvard Medical School, Boston, MA, USA. Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA. Department of Hematology, Oncology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany ### 2076052###Speaker###Clinician Scientiest/ Research Fellow###University Medical Center Hamburg-Eppendorf, Germany / Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Department of Medicine, Harvard Medical School, Boston, MA, USA. Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA. Department of Hematology, Oncology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany###
Speaker: Lisa B. Leypoldt, MD (she/her/hers) – University Medical Center Hamburg-Eppendorf, Germany / Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Department of Medicine, Harvard Medical School, Boston, MA, USA. Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA. Department of Hematology, Oncology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
### she/her/hers
OA-44: Pomalidomide, bortezomib, and dexamethasone vs bortezomib and dexamethasone in relapsed or refractory multiple myeloma (OPTIMISMM): final survival outcomes from a randomized, open-label, phase 3 trial

Meral Beksac, MD (she/her/hers) – Ankara University ### 1443293###Speaker###Professor of Hematology###Ankara University###
Speaker: Meral Beksac, MD (she/her/hers) – Ankara University
### she/her/hers
OA-45: Pharmacokinetic and correlative analysis of ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma in the CARTITUDE-4 trial

Carlos Fernandez de Larrea, MD, PhD – Hospital Clínic de Barcelona ### 1949895###Speaker###Consultant, Amyloidosis and Myeloma Unit, Department of Hematology###Hospital Clínic de Barcelona###
Speaker: Carlos Fernandez de Larrea, MD, PhD – Hospital Clínic de Barcelona
###
OA-46: Epigenetic regulation of CD38/48 by KDM6A mediates NK cell response in multiple myeloma

Jiye Liu, PhD (he/him/his) – Dana-Farber Cancer Institute ### 1442056###Speaker###Instructor###Dana-Farber Cancer Institute###
Speaker: Jiye Liu, PhD (he/him/his) – Dana-Farber Cancer Institute
### he/him/his
OA-47: Additional analysis of CARTITUDE-4: Cilta-cel vs standard of care (PVd or DPd) in lenalidomide-refractory patients with multiple myeloma and 1-3 prior lines of therapy

Salomon Manier, MD, PhD – Centre Hospitalier Universitaire de Lille, Université de Lille, Lille, France ### 1395123###Speaker###Professor of Medicine###Centre Hospitalier Universitaire de Lille, Université de Lille, Lille, France###
Speaker: Salomon Manier, MD, PhD – Centre Hospitalier Universitaire de Lille, Université de Lille, Lille, France
###
OA-48: Isatuximab plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients With Relapsed Multiple Myeloma (IKEMA): Final Overall Survival Analysis

Philippe Moreau, MD – University Hospital Hôtel-Dieu, Nantes, France ### 1395078###Speaker###Head of Hematology###University Hospital Hôtel-Dieu, Nantes, France###
Speaker: Philippe Moreau, MD – University Hospital Hôtel-Dieu, Nantes, France
###
OA-49: Mezigdomide (MEZI) plus dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): results from the CC-92480-MM-002 trial

Albert Oriol, PhD (he/him/his) – Catalan Institute of Oncology and Josep Carreras Institute, Hospital Germans Trias i Pujol, Badalona, Spain ### 1441780###Speaker###Head of the Clinical Research Unit###Catalan Institute of Oncology and Josep Carreras Institute, Hospital Germans Trias i Pujol, Badalona, Spain###
Speaker: Albert Oriol, PhD (he/him/his) – Catalan Institute of Oncology and Josep Carreras Institute, Hospital Germans Trias i Pujol, Badalona, Spain
### he/him/his
OA-51: Preliminary Recommendations for Prevention and Management of Infections, Hypogammaglobulinemia, and Neutropenia During Treatment With Teclistamab Based on Experience From the MajesTEC-1 Study

Niels van de Donk, MD PhD (he/him/his) – Amsterdam UMC ### 1949889###Speaker###professor###Amsterdam UMC###
Speaker: Niels van de Donk, MD PhD (he/him/his) – Amsterdam UMC
### he/him/his
OA-52: Results From the Randomized, Open-Label Phase 3 CANOVA Study of Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in Patients With t(11;14)-Positive Relapsed/Refractory Multiple Myeloma

Maria-Victoria Mateos, PhD (she/her/hers) – University Hospital of Salamanca ### 1949876###Speaker###Head of Unit###University Hospital of Salamanca###
Speaker: Maria-Victoria Mateos, PhD (she/her/hers) – University Hospital of Salamanca
### she/her/hers
OA-53: Peripheral Blood and Bone Marrow Residual Disease Negativity to Identify a Subgroup of Newly Diagnosed Multiple Myeloma Patients with Long Term Disease Control

Noemi Puig, MD, PhD – Hospital Universitario de Salamanca, Instituto de investigación biomédica de Salamanca (IBSAL) ### 1395124###Speaker###Hematologist###Hospital Universitario de Salamanca, Instituto de investigación biomédica de Salamanca (IBSAL)###
Speaker: Noemi Puig, MD, PhD – Hospital Universitario de Salamanca, Instituto de investigación biomédica de Salamanca (IBSAL)
###
OA-54: Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone with tandem transplant in high-risk newly diagnosed myeloma patients: final results of the phase 2 study IFM 2018-04

Cyrille Touzeau, MD, PhD – CHU Nantes ### 1395058###Speaker###Hematologist###CHU Nantes###
Speaker: Cyrille Touzeau, MD, PhD – CHU Nantes
###
OA-55: Real world experience of patients treated with teclistamab: a BCMA-directed bispecific t-cell engaging therapy for multiple myeloma

Shonali Midha, MD – Dana Farber Cancer Institute ### 2076281###Speaker###Physician###Dana Farber Cancer Institute###
Speaker: Shonali Midha, MD – Dana Farber Cancer Institute
###
One Size Does Not Fit All! Individualizing Treatment in NDMM

Xavier P. Leleu, MD, PhD (he/him/his) – Hospital La Mileterie, Poitiers, France ### 1395160###Speaker###Head of Myeloma Clinic and Head of Department of Haematology###Hospital La Mileterie, Poitiers, France###
Speaker: Xavier P. Leleu, MD, PhD (he/him/his) – Hospital La Mileterie, Poitiers, France
### he/him/his
Open

Monica Morris, MSc, RN – Myeloma UK ### 1408999###Co-Chair###Clinical Practice Services ###Myeloma UK###
Co-Chair: Monica Morris, MSc, RN – Myeloma UK
### @@@ Ioanna Tsatsou ### 1996608###Co-Chair#########
Co-Chair: Ioanna Tsatsou
###
Optimizing supportive care management

Evangelos Terpos, MD, PhD (he/him/his) – Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Greece ### 1395152###Speaker###Professor###Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Greece###
Speaker: Evangelos Terpos, MD, PhD (he/him/his) – Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Greece
### he/him/his
Origin of MM cells

Nikhil Munshi, MD – Dana-Farber Cancer Institute, Harvard Medical School ### 1395035###Chair###Kraft Family Chair, Director of Basic and Correlative Science, Professor of Medicine, Harvard Medical School ###Dana-Farber Cancer Institute, Harvard Medical School###
Chair: Nikhil Munshi, MD – Dana-Farber Cancer Institute, Harvard Medical School
### @@@ Faith E. Davies, MD (she/her/hers) – Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA ### 1395145###Co-Chair###Professor of Medicine, Director of the Center for Blood Cancers Director of the Clinical Myeloma Pro###Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA###
Co-Chair: Faith E. Davies, MD (she/her/hers) – Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA
### she/her/hers
P
Plenary Session

Robert Z. Orlowski, PhD, MD (he/him/his) – The University of Texas MD Anderson Cancer Center ### 1949892###Co-Chair###Florence Maude Thomas Cancer Research ProfessorDirector, Myeloma Section & Deputy Department ChairThe Department of Lymphoma & Myeloma###The University of Texas MD Anderson Cancer Center###
Co-Chair: Robert Z. Orlowski, PhD, MD (he/him/his) – The University of Texas MD Anderson Cancer Center
### he/him/his @@@ Qing Yi, MD, PhD (he/him/his) – Houston Methodist Neal Cancer Center ### 1409108###Co-Chair###Associate Director###Houston Methodist Neal Cancer Center###
Co-Chair: Qing Yi, MD, PhD (he/him/his) – Houston Methodist Neal Cancer Center
### he/him/his
PNC-27: A Novel Effective Strategy for Targeting the Achilles' Heel of Multiple Myeloma

Flavia Pichiorri, PhD (she/her/hers) – City of Hope ### 2129889###Speaker###Professor ###City of Hope ###
Speaker: Flavia Pichiorri, PhD (she/her/hers) – City of Hope
### she/her/hers
Practical Aspects of Immunotherapy

Jesus San Miguel, PhD. MD. (he/him/his) – Clínica Universidad de Navarra ### 1949888###Chair###Director of Clinical & Translational Medicine of University of Navarra###Clínica Universidad de Navarra###
Chair: Jesus San Miguel, PhD. MD. (he/him/his) – Clínica Universidad de Navarra
### he/him/his @@@ Noopur Raje, MD – Massachusetts General Hospital Cancer Center ### 1395114###Co-Chair###Director, Center for Multiple Myeloma###Massachusetts General Hospital Cancer Center###
Co-Chair: Noopur Raje, MD – Massachusetts General Hospital Cancer Center
###
President's Address

Nikhil Munshi, MD – Dana-Farber Cancer Institute, Harvard Medical School ### 1395035###Speaker###Kraft Family Chair, Director of Basic and Correlative Science, Professor of Medicine, Harvard Medical School ###Dana-Farber Cancer Institute, Harvard Medical School###
Speaker: Nikhil Munshi, MD – Dana-Farber Cancer Institute, Harvard Medical School
###
Prevention and monitoring of infections with immunotherapies

Joshua Richter, MD – Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA ### 1441830###Speaker###Associate Professor of Medicine###Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA###
Speaker: Joshua Richter, MD – Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
###
Q
Q&A and close
Q&A session

Rakesh Popat, MD, PhD – University College London Hospitals NHS Foundation Trust ### 1441806###Chair###Consultant Haematologist & Associate Professor###University College London Hospitals NHS Foundation Trust###
Chair: Rakesh Popat, MD, PhD – University College London Hospitals NHS Foundation Trust
###
R
Regulatory Perspective on MRD in hematological malignancies

Nicole Gormley, MD – U.S. Food and Drug Administration ### 1456920###Speaker###Division Director ###U.S. Food and Drug Administration###
Speaker: Nicole Gormley, MD – U.S. Food and Drug Administration
###
Riney Research Symposium

Nikhil Munshi, MD – Dana-Farber Cancer Institute, Harvard Medical School ### 1395035###Co-Chair###Kraft Family Chair, Director of Basic and Correlative Science, Professor of Medicine, Harvard Medical School ###Dana-Farber Cancer Institute, Harvard Medical School###
Co-Chair: Nikhil Munshi, MD – Dana-Farber Cancer Institute, Harvard Medical School
### @@@ Kenneth C. Anderson, MD – The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA ### 1395077###Co-Chair###Professor in Medicine###The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA###
Co-Chair: Kenneth C. Anderson, MD – The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
###
Role of tumor microenvironment in drug resistance

Suzanne Lentzsch, MD, PhD (she/her/hers) – Columbia University ### 1395075###Speaker###Professor of Medicine###Columbia University###
Speaker: Suzanne Lentzsch, MD, PhD (she/her/hers) – Columbia University
### she/her/hers
Round table discussion

Wee Joo Chng, MB ChB, PhD, FRCP (UK), FRCPath (UK), FAMS – National University Cancer Institute, Singapore ### 1395044###Panelist###Director and Senior Consultant###National University Cancer Institute, Singapore###
Panelist: Wee Joo Chng, MB ChB, PhD, FRCP (UK), FRCPath (UK), FAMS – National University Cancer Institute, Singapore
### @@@ Sundar Jagannath, MD, FASCO – Mount Sinai Medical Center, New York, NY, USA ### 1395142###Panelist###Chair for Multiple Myeloma and Professor of Medicine###Mount Sinai Medical Center, New York, NY, USA###
Panelist: Sundar Jagannath, MD, FASCO – Mount Sinai Medical Center, New York, NY, USA
### @@@ Hira Mian, MD, MSc, FRCPC – McMaster University, Hamilton, Ontario, Canada ### 1719006###Panelist###Assistant Professor###McMaster University, Hamilton, Ontario, Canada###
Panelist: Hira Mian, MD, MSc, FRCPC – McMaster University, Hamilton, Ontario, Canada
### @@@ Cristina Gasparetto, MD (she/her/hers) – Department of Medicine, Duke University Cancer Institute, Durham, NC ### 1441876###Panelist###Professor of Medicine###Department of Medicine, Duke University Cancer Institute, Durham, NC###
Panelist: Cristina Gasparetto, MD (she/her/hers) – Department of Medicine, Duke University Cancer Institute, Durham, NC
### she/her/hers @@@ Mohamad Mohty, MD, PhD – Sorbonne University, Saint-Antoine Hospital, AP-HP INSERM UMRs 938, Paris, France ### 1395090###Panelist###Professor of Hematology###Sorbonne University, Saint-Antoine Hospital, AP-HP INSERM UMRs 938, Paris, France###
Panelist: Mohamad Mohty, MD, PhD – Sorbonne University, Saint-Antoine Hospital, AP-HP INSERM UMRs 938, Paris, France
###
Round table discussion

Jesus G. Berdeja, MD – Sarah Cannon Research Institute ### 1395097###Panelist###Director of Multiple Myeloma Research###Sarah Cannon Research Institute###
Panelist: Jesus G. Berdeja, MD – Sarah Cannon Research Institute
### @@@ Ivan Borrello, MD – Tampa General Hospital ### 1409073###Panelist###Director Multiple Myeloma, BMT and Cell Therapy###Tampa General Hospital###
Panelist: Ivan Borrello, MD – Tampa General Hospital
### @@@ Tom Martin, MD (he/him/his) – UCSF ### 1949890###Panelist###Associate Chief, Hematology, Director Blood and Marrow Transplant and Cell Therapy###UCSF###
Panelist: Tom Martin, MD (he/him/his) – UCSF
### he/him/his @@@ Monika Engelhardt ### 1949891###Panelist#########
Panelist: Monika Engelhardt
### @@@ Sham Mailankody, MBBS – Memorial Sloan Kettering Cancer Center ### 1395111###Panelist###Associate Attending###Memorial Sloan Kettering Cancer Center###
Panelist: Sham Mailankody, MBBS – Memorial Sloan Kettering Cancer Center
###
Round table discussion

P. Joy Ho, MBBS DPhil FRACP FRCPA (she/her/hers) – Institute of Haematology, Royal Prince Alfred Hospital ### 1949884###Panelist###Clinical Director###Institute of Haematology, Royal Prince Alfred Hospital###
Panelist: P. Joy Ho, MBBS DPhil FRACP FRCPA (she/her/hers) – Institute of Haematology, Royal Prince Alfred Hospital
### she/her/hers @@@ Keith Stewart, MB ChB – Princess Margaret Cancer Centre, University Health Network ### 1395117###Panelist###Medical Director, Princess Margaret Cancer Centre and VP Cancer, University Health Network###Princess Margaret Cancer Centre, University Health Network###
Panelist: Keith Stewart, MB ChB – Princess Margaret Cancer Centre, University Health Network
### @@@ MELETIOS DIMOPOULOS, MD (he/him/his) – Department of Clinical Therapeutics/Medical School/National and Kapodistrian University of Athens ### 1949885###Panelist###Professor###Department of Clinical Therapeutics/Medical School/National and Kapodistrian University of Athens###
Panelist: MELETIOS DIMOPOULOS, MD (he/him/his) – Department of Clinical Therapeutics/Medical School/National and Kapodistrian University of Athens
### he/him/his @@@ Donna E. Reece, MD – University Health Network, Princess Margaret Cancer Centre ### 1395149###Panelist###Professor of Medicine, Director, Clinical Trials Program for Multiple Myeloma and Related Diseases###University Health Network, Princess Margaret Cancer Centre###
Panelist: Donna E. Reece, MD – University Health Network, Princess Margaret Cancer Centre
### @@@ Ajai Chari, MD, PhD – University of California, San Francisco ### 1395089###Panelist###Director of Multiple Myeloma Program Professor of Clinical Medicine###University of California, San Francisco###
Panelist: Ajai Chari, MD, PhD – University of California, San Francisco
### @@@ Bindu Kanapuru ### 2102754###Panelist#########
Panelist: Bindu Kanapuru
###
Round table discussion

Sonja Zweegman, MD, PhD – Amsterdam UMC ### 1409107###Panelist###Head of department hematology###Amsterdam UMC###
Panelist: Sonja Zweegman, MD, PhD – Amsterdam UMC
### @@@ Herve Avet-Loiseau, MD, PhD (he/him/his) – IUC-Oncopole ### 1395049###Panelist###Head###IUC-Oncopole###
Panelist: Herve Avet-Loiseau, MD, PhD (he/him/his) – IUC-Oncopole
### he/him/his @@@ Wilson I. Gonsalves, MD – Mayo Clinic, Rochester ### 1395132###Panelist###Consultant, Division of Hematology, Department of Internal Medicine###Mayo Clinic, Rochester###
Panelist: Wilson I. Gonsalves, MD – Mayo Clinic, Rochester
###
Round table discussion

Sergio Giralt, MD – Memorial Sloan Kettering Cancer Center ### 1395141###Panelist###Professor###Memorial Sloan Kettering Cancer Center###
Panelist: Sergio Giralt, MD – Memorial Sloan Kettering Cancer Center
### @@@ Thierry Facon, MD – University of Lille, CHU Lille, Service des Maladies du Sang, Lille, France ### 1395081###Panelist###Pr###University of Lille, CHU Lille, Service des Maladies du Sang, Lille, France###
Panelist: Thierry Facon, MD – University of Lille, CHU Lille, Service des Maladies du Sang, Lille, France
### @@@ Jean-Luc Harousseau, MD – INSTITUT DE CANCEROLOGIE DE L'OUEST FRANCE ### 1395104###Panelist###SCIENTIFIC DIRECTOR###INSTITUT DE CANCEROLOGIE DE L'OUEST FRANCE###
Panelist: Jean-Luc Harousseau, MD – INSTITUT DE CANCEROLOGIE DE L'OUEST FRANCE
### @@@ Vania Hungria, MD, PhD – Department of Hematology, Clinica São Germano, São Paulo, Brazil ### 1395161###Panelist###Associate Professor###Department of Hematology, Clinica São Germano, São Paulo, Brazil###
Panelist: Vania Hungria, MD, PhD – Department of Hematology, Clinica São Germano, São Paulo, Brazil
### @@@ Michele Cavo (he/him/his) – IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Università degli Studi di Bologna, Bologna, Italy ### 1395079###Panelist###Professor of Haematology###IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Università degli Studi di Bologna, Bologna, Italy###
Panelist: Michele Cavo (he/him/his) – IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Università degli Studi di Bologna, Bologna, Italy
### he/him/his @@@ Bindu Kanapuru ### 2102754###Panelist#########
Panelist: Bindu Kanapuru
###
Round table discussion

Rafael Fonseca, MD – Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ, USA ### 1395047###Panelist###Chief Innovation Officer###Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ, USA###
Panelist: Rafael Fonseca, MD – Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ, USA
### @@@ Andrew Spencer, MBBS FRACP, FRCPA, DM – Alfred Health-Monash University ### 1441802###Panelist###Professor###Alfred Health-Monash University###
Panelist: Andrew Spencer, MBBS FRACP, FRCPA, DM – Alfred Health-Monash University
### @@@ Rodger E. Tiedemann, MD, PhD (he/him/his) – Princess Margaret Cancer Centre ### 1395134###Panelist###Senior Scientist, Hematologist###Princess Margaret Cancer Centre###
Panelist: Rodger E. Tiedemann, MD, PhD (he/him/his) – Princess Margaret Cancer Centre
### he/him/his @@@ Marta Chesi, PhD (she/her/hers) – Mayo Clinic Arizona ### 1395120###Panelist###Associate Professor###Mayo Clinic Arizona###
Panelist: Marta Chesi, PhD (she/her/hers) – Mayo Clinic Arizona
### she/her/hers
Roundtable discussion: Practical considerations (eligibility, access, and benefit/risk)
S
Single cell approach to defining mechanisms of progression for SMM to MM

Irene Ghobrial, MD (she/her/hers) – Dana-Farber Cancer Institute, Boston, MA, USA ### 1395041###Speaker###Professor of Medicine, Harvard Medical School###Dana-Farber Cancer Institute, Boston, MA, USA###
Speaker: Irene Ghobrial, MD (she/her/hers) – Dana-Farber Cancer Institute, Boston, MA, USA
### she/her/hers
Special Career Development Session: Round table discussion

Suzanne Lentzsch, MD, PhD (she/her/hers) – Columbia University ### 1395075###Speaker###Professor of Medicine###Columbia University###
Speaker: Suzanne Lentzsch, MD, PhD (she/her/hers) – Columbia University
### she/her/hers @@@ Andrew R. Branagan, MD, PhD – Massachusetts General Hospital ### 1442194###Speaker###Attending Physician###Massachusetts General Hospital###
Speaker: Andrew R. Branagan, MD, PhD – Massachusetts General Hospital
### @@@ Ravi Vij, MD MBA – Washington University in St. Louis ### 1395060###Speaker###Professor###Washington University in St. Louis###
Speaker: Ravi Vij, MD MBA – Washington University in St. Louis
###
Special Session

MELETIOS DIMOPOULOS, MD (he/him/his) – Department of Clinical Therapeutics/Medical School/National and Kapodistrian University of Athens ### 1949885###Co-Chair###Professor###Department of Clinical Therapeutics/Medical School/National and Kapodistrian University of Athens###
Co-Chair: MELETIOS DIMOPOULOS, MD (he/him/his) – Department of Clinical Therapeutics/Medical School/National and Kapodistrian University of Athens
### he/him/his @@@ Efstathios Kastritis, MD, PhD (he/him/his) – National and Kapodistrian University of Athens ### 1949897###Co-Chair###Professor of Medicine ###National and Kapodistrian University of Athens ###
Co-Chair: Efstathios Kastritis, MD, PhD (he/him/his) – National and Kapodistrian University of Athens
### he/him/his
Striking the balance: challenges in myeloma supportive care

Evangelos Terpos, MD, PhD (he/him/his) – Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Greece ### 1395152###Speaker###Professor###Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Greece###
Speaker: Evangelos Terpos, MD, PhD (he/him/his) – Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Greece
### he/him/his
Summarize Abstract

Faith E. Davies, MD (she/her/hers) – Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA ### 1395145###Speaker###Professor of Medicine, Director of the Center for Blood Cancers Director of the Clinical Myeloma Pro###Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA###
Speaker: Faith E. Davies, MD (she/her/hers) – Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA
### she/her/hers
Summarize Abstract

Kenneth C. Anderson, MD – The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA ### 1395077###Speaker###Professor in Medicine###The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA###
Speaker: Kenneth C. Anderson, MD – The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
###
Summarize Abstract

Samir Parekh, MD – Mount Sinai Medical Center, New York, NY, USA ### 1441821###Speaker###Professor of Medicine, Hematology-Oncology & Oncological Sciences###Mount Sinai Medical Center, New York, NY, USA###
Speaker: Samir Parekh, MD – Mount Sinai Medical Center, New York, NY, USA
###
Summarize Abstract

Paola Neri, MD PhD – Arnie Charbonneau Cancer Research Institute, University of Calgary ### 1409064###Speaker###Associate Professor###Arnie Charbonneau Cancer Research Institute, University of Calgary###
Speaker: Paola Neri, MD PhD – Arnie Charbonneau Cancer Research Institute, University of Calgary
###
Summarize Abstract

Tom Martin, MD (he/him/his) – UCSF ### 1949890###Speaker###Associate Chief, Hematology, Director Blood and Marrow Transplant and Cell Therapy###UCSF###
Speaker: Tom Martin, MD (he/him/his) – UCSF
### he/him/his
Summarize Abstract

Sagar Lonial, MD, FACP – Emory University School of Medicine, Atlanta, GA, USA ### 1395113###Speaker###Professor and Chair###Emory University School of Medicine, Atlanta, GA, USA###
Speaker: Sagar Lonial, MD, FACP – Emory University School of Medicine, Atlanta, GA, USA
###
T
The role of exercise in building resilience

Orla McCourt, PhD MCSP – University College London NHS Foundation Trust ### 1718958###Speaker###Clinical Specialist Physiotherapist###University College London NHS Foundation Trust###
Speaker: Orla McCourt, PhD MCSP – University College London NHS Foundation Trust
###
The Tailor-made Approach: Insights from Patient Cases

Elizabeth O'Donnell, MD – Massachusetts General Hospital ### 1395154###Speaker###Assistant Professor###Massachusetts General Hospital###
Speaker: Elizabeth O'Donnell, MD – Massachusetts General Hospital
###
Time for T? Expanding treatment paradigms in the later-line RR setting

Roberto Mina, MD – European Myeloma Network, Italy ### 1441761###Speaker###Investigator###European Myeloma Network, Italy###
Speaker: Roberto Mina, MD – European Myeloma Network, Italy
###
Time to combine? Evolving treatment options in NDMM

Leo Rasche, MD – Department of Internal Medicine II, University Hospital, 97080 Würzburg, Germany ### 1442365###Speaker###associate professor###Department of Internal Medicine II, University Hospital, 97080 Würzburg, Germany###
Speaker: Leo Rasche, MD – Department of Internal Medicine II, University Hospital, 97080 Würzburg, Germany
###
Time to tailor? Treatment selection at first relapse and beyond

Michel Delforge, MD/Phd – University of Leuven, Leuven, Belgium ### 1395153###Speaker###Professor of Medicine###University of Leuven, Leuven, Belgium###
Speaker: Michel Delforge, MD/Phd – University of Leuven, Leuven, Belgium
###
Treatment Fitness: frailty adapted treatment approaches

Gordon Cook, PhD – Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK ### 1395086###Speaker###Clinical Professor###Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK###
Speaker: Gordon Cook, PhD – Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK
###
Treatment options for elderly patients in early RRMM: immunomodulatory agents, proteasome inhibitors, anti-CD38 antibodies, and more

Paul G. Richardson, MD – Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA ### 1441820###Speaker###Clinical Program Leader and Director of Clinical Research###Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA###
Speaker: Paul G. Richardson, MD – Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
###
Triple Class Refractory Myeloma

Philippe Moreau, MD – University Hospital Hôtel-Dieu, Nantes, France ### 1395078###Chair###Head of Hematology###University Hospital Hôtel-Dieu, Nantes, France###
Chair: Philippe Moreau, MD – University Hospital Hôtel-Dieu, Nantes, France
### @@@ Sagar Lonial, MD, FACP – Emory University School of Medicine, Atlanta, GA, USA ### 1395113###Co-Chair###Professor and Chair###Emory University School of Medicine, Atlanta, GA, USA###
Co-Chair: Sagar Lonial, MD, FACP – Emory University School of Medicine, Atlanta, GA, USA
###
U
Update on CAR T Cell Therapy Development

Hermann Einsele, MD, FRCP (he/him/his) – Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Würzburg, Germany ### 1395031###Speaker###Clinic Director of Medicine###Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Würzburg, Germany###
Speaker: Hermann Einsele, MD, FRCP (he/him/his) – Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Würzburg, Germany
### he/him/his
W
Waldenstrom

Steven Treon, MD, PhD, FACP, FRCP (he/him/his) – Dana Farber Cancer Institute ### 1395107###Speaker###Professor-Harvard Medical School, Director-Bing Center for WM###Dana Farber Cancer Institute###
Speaker: Steven Treon, MD, PhD, FACP, FRCP (he/him/his) – Dana Farber Cancer Institute
### he/him/his
Welcome and Introduction

Hermann Einsele, MD, FRCP (he/him/his) – Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Würzburg, Germany ### 1395031###Speaker###Clinic Director of Medicine###Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Würzburg, Germany###
Speaker: Hermann Einsele, MD, FRCP (he/him/his) – Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Würzburg, Germany
### he/him/his
Welcome and Introduction

Joseph Mikhael, MD – Translational Genomics Research Institute (TGen), City of Hope Cancer Center ### 1409001###Speaker###Professor in Applied Cancer Research and Drug Discovery###Translational Genomics Research Institute (TGen), City of Hope Cancer Center###
Speaker: Joseph Mikhael, MD – Translational Genomics Research Institute (TGen), City of Hope Cancer Center
###
What is the ideal duration of treatment - MRD guided or till progression?

Kwee L. Yong, PhD (she/her/hers) – University College London Cancer Institute, London, UK ### 1395115###Speaker###Professor of Haematology###University College London Cancer Institute, London, UK###
Speaker: Kwee L. Yong, PhD (she/her/hers) – University College London Cancer Institute, London, UK
### she/her/hers
What is the optimal upfront therapy - 3 or 4 drugs?

Saad Z. Usmani, MD MBA FACP – Memorial Sloan Kettering Cancer Center ### 1395084###Speaker###Chief of Myeloma Service###Memorial Sloan Kettering Cancer Center###
Speaker: Saad Z. Usmani, MD MBA FACP – Memorial Sloan Kettering Cancer Center
###
Who needs an autologous stem cell transplant upfront?

Aurore Perrot, MD, PhD – CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d’Hématologie, Toulouse, France ### 1416883###Speaker###Professor###CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d’Hématologie, Toulouse, France###
Speaker: Aurore Perrot, MD, PhD – CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d’Hématologie, Toulouse, France
###
Y
Young Investigator Awards